Advanced search

Vol 18, No 5 (2022)
Review paper
Published online: 2021-07-15

open access

View PDF Download PDF file
Page views 4185
Article views/downloads 419
Get Citation

Connect on Social Media

Connect on Social Media

Dual impact from coincide potential complications of cancer therapy and sarcopenia: a narrative review

Anmar Al-Taie1, Aygül Koseoğlu2
DOI: 10.5603/OCP.2021.0023
Oncol Clin Pract 2022;18(5):302-325.

Abstract

Sarcopenia is a disorder of progressive loss of skeletal muscle mass and strength that is linked with multiple complications, decreased physical activity, lower quality of life and accelerated mortality rate. It is more common among cancer patients and identified with reduced tolerance by the toxic effects from cancer therapy, negative outcomes, lowered response and overall survival rate. This narrative review aims to demonstrate the dual impact from the co-occurrence of cancer therapy; chemotherapy, radiotherapy, immunotherapy, and sarcopenia alongside the potential complications from their coincide effects on cancer prognosis. By searching through data sets, all articles that focused on sarcopenia and cancer therapy were collected in the indexed journals between the years 2000 and 2021 that could provide findings for the potential complications from the coinciding effects of cancer therapy and sarcopenia in cancer patients receiving chemo-radio- and immunotherapy. Outcome measures were the rate of studies showing potential complications from the co-occurrence of cancer therapies and sarcopenia. A total of hundred-two cohort studies were enrolled. The majority were about chemotherapy and sarcopenia (45%). About 56.9% of the studies designed as retrospective analysis, and a high proportion were about chemotherapy and sarcopenia (21.6%). About 63.7% of the studies reported skeletal muscle index as the primary marker. Lower than half of the reviewed studies revealed a significant increase in the rate of sarcopenia (47%). The direct toxic effects of chemotherapy on skeletal muscle were reported in 13.7% of the studies. Studies that reported the impact of sarcopenia on a reduction in chemotherapy cycles were about 10.8%. About 11.8% and 14.7% of the studies showed lowered overall survival by the coinciding impact of chemotherapy/radiotherapy and sarcopenia, respectively. In conclusion, the evaluation of sarcopenia in cancer patients should be considered a primary part of oncological care in cancer patients as there are potential complications and poor survival from the co-occurrence of sarcopenia and different cancer therapies.

Keywords: cancerchemotherapyimmunotherapyradiotherapyskeletal musclesarcopenia

Article available in PDF format

View PDF Download PDF file

References

  1. Santilli V. Clinical definition of sarcopenia. Clinical Cases in Mineral and Bone Metabolism. 2014.
    CrossRef
  2. Rosenberg IH, Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997; 127(5 Suppl): 990S–991S.
    CrossRefPubMed
  3. Muscaritoli M, Anker SD, Argilés J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr. 2010; 29(2): 154–159.
    CrossRefPubMed
  4. Kenis C, Decoster L, Van Puyvelde K, et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014; 32(1): 19–26.
    CrossRefPubMed
  5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412–423.
    CrossRefPubMed
  6. Kwan P, Kwan P. Sarcopenia, a neurogenic syndrome? J Aging Res. 2013; 2013: 791679.
    CrossRefPubMed
  7. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012; 8(8): 457–465.
    CrossRefPubMed
  8. Quinn LS. Interleukin-15: a muscle-derived cytokine regulating fat-to-lean body composition. J Anim Sci. 2008; 86(14 Suppl): E75–E83.
    CrossRefPubMed
  9. Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY). 2012; 4(8): 535–546.
    CrossRefPubMed
  10. Roy P, Chowdhury S, Roy HK. Exercise-induced myokines as emerging therapeutic agents in colorectal cancer prevention and treatment. Future Oncol. 2018; 14(4): 309–312.
    CrossRefPubMed
  11. Steensberg A, Fischer CP, Keller C, et al. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab. 2003; 285(2): E433–E437.
    CrossRefPubMed
  12. Lin JX, Lin JP, Xie JW, et al. Prognostic Value and Association of Sarcopenia and Systemic Inflammation for Patients with Gastric Cancer Following Radical Gastrectomy. Oncologist. 2019; 24(11): e1091–e1101.
    CrossRefPubMed
  13. Patel HJ, Patel BM. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 2017; 170: 56–63.
    CrossRefPubMed
  14. Janssen I, Shepard DS, Katzmarzyk PT, et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004; 52(1): 80–85.
    CrossRefPubMed
  15. Gale CR, Martyn CN, Cooper C, et al. Grip strength, body composition, and mortality. Int J Epidemiol. 2007; 36(1): 228–235.
    CrossRefPubMed
  16. Zargar H, Almassi N, Kovac E, et al. Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Bladder Cancer. 2017; 3(1): 57–63.
    CrossRefPubMed
  17. Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 2016; 57: 58–67.
    CrossRefPubMed
  18. Levolger S, van Vugt JLA, de Bruin RWF, et al. Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies. Br J Surg. 2015; 102(12): 1448–1458.
    CrossRefPubMed
  19. Kawamura T, Makuuchi R, Tokunaga M, et al. Long-Term Outcomes of Gastric Cancer Patients with Preoperative Sarcopenia. Ann Surg Oncol. 2018; 25(6): 1625–1632.
    CrossRefPubMed
  20. Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MAE, et al. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2016; 34(12): 1339–1344.
    CrossRefPubMed
  21. Liu J, Motoyama S, Sato Y, et al. Decreased Skeletal Muscle Mass After Neoadjuvant Therapy Correlates with Poor Prognosis in Patients with Esophageal Cancer. Anticancer Res. 2016; 36(12): 6677–6685.
    CrossRefPubMed
  22. Ma DW, Cho Y, Jeon MJ, et al. Relationship Between Sarcopenia and Prognosis in Patient With Concurrent Chemo-Radiation Therapy for Esophageal Cancer. Front Oncol. 2019; 9: 366.
    CrossRefPubMed
  23. Paireder M, Asari R, Kristo I, et al. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer. Eur J Surg Oncol. 2017; 43(2): 478–484.
    CrossRefPubMed
  24. Järvinen T, Ilonen I, Kauppi J, et al. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. World J Surg Oncol. 2018; 16(1): 27.
    CrossRefPubMed
  25. Choi Y, Oh DY, Kim TY, et al. Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index. PLoS One. 2015; 10(10): e0139749.
    CrossRefPubMed
  26. Jung HW, Kim JW, Kim JY, et al. Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer. 2015; 23(3): 687–694.
    CrossRefPubMed
  27. Miyamoto Y, Baba Y, Sakamoto Y, et al. Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer. PLoS One. 2015; 10(6): e0129742.
    CrossRefPubMed
  28. Derksen JWG, Kurk SA, Oskam MJ, et al. Factors Contributing to Cancer-Related Muscle Wasting During First-Line Systemic Treatment for Metastatic Colorectal Cancer. JNCI Cancer Spectr. 2019; 3(2): pkz014.
    CrossRefPubMed
  29. Go SI, Park MiJ, Song HN, et al. Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. Support Care Cancer. 2016; 24(5): 2075–2084.
    CrossRefPubMed
  30. Prado CMM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009; 15(8): 2920–2926.
    CrossRefPubMed
  31. Rutten IJG, van Dijk DPJ, Kruitwagen RF, et al. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 2016; 7(4): 458–466.
    CrossRefPubMed
  32. Awad S, Tan BH, Cui H, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr. 2012; 31(1): 74–77.
    CrossRefPubMed
  33. Yip C, Goh V, Davies A, et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. Eur Radiol. 2014; 24(5): 998–1005.
    CrossRefPubMed
  34. Daly LE, Ní Bhuachalla ÉB, Power DG, et al. Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle. 2018; 9(2): 315–325.
    CrossRefPubMed
  35. Guinan EM, Doyle SL, Bennett AE, et al. Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance. Support Care Cancer. 2018; 26(5): 1569–1576.
    CrossRefPubMed
  36. Cooper AB, Slack R, Fogelman D, et al. Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer. Ann Surg Oncol. 2015; 22(7): 2416–2423.
    CrossRefPubMed
  37. Benjamin AJ, Buschmann MM, Zhang SQ, et al. The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer. J Geriatr Oncol. 2018; 9(4): 367–372.
    CrossRefPubMed
  38. Sandini M, Patino M, Ferrone CR, et al. Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. JAMA Surg. 2018; 153(9): 809–815.
    CrossRefPubMed
  39. Poterucha T, Burnette B, Jatoi A. A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab. Med Oncol. 2012; 29(2): 1005–1009.
    CrossRefPubMed
  40. Eriksson S, Nilsson JH, Strandberg Holka P, et al. The impact of neoadjuvant chemotherapy on skeletal muscle depletion and preoperative sarcopenia in patients with resectable colorectal liver metastases. HPB (Oxford). 2017; 19(4): 331–337.
    CrossRefPubMed
  41. Nattenmüller J, Wochner R, Muley T, et al. Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients. PLoS One. 2017; 12(1): e0169136.
    CrossRefPubMed
  42. Goncalves MD, Taylor S, Halpenny DF, et al. Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer. Clin Radiol. 2018; 73(5): 505.e1–505.e8.
    CrossRefPubMed
  43. Zargar H, Almassi N, Kovac E, et al. Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Bladder Cancer. 2017; 3(1): 57–63.
    CrossRefPubMed
  44. Rimar KJ, Glaser AP, Kundu S, et al. Changes in Lean Muscle Mass Associated with Neoadjuvant Platinum-Based Chemotherapy in Patients with Muscle Invasive Bladder Cancer. Bladder Cancer. 2018; 4(4): 411–418.
    CrossRefPubMed
  45. Prado CMM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9(7): 629–635.
    CrossRefPubMed
  46. Stene GB, Helbostad JL, Amundsen T, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 2015; 54(3): 340–348.
    CrossRefPubMed
  47. Englesbe MJ, Patel SP, He K, et al. Sarcopenia and mortality after liver transplantation. J Am Coll Surg. 2010; 211(2): 271–278.
    CrossRefPubMed
  48. Garcia JM, Scherer T, Chen Ja, et al. Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice. Endocrinology. 2013; 154(9): 3118–3129.
    CrossRefPubMed
  49. Rier HN, Jager A, Sleijfer S, et al. Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2018; 168(1): 95–105.
    CrossRefPubMed
  50. Chen JA, Splenser A, Guillory B, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015; 6(2): 132–143.
    CrossRefPubMed
  51. Gilliam LAA, St Clair DK. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal. 2011; 15(9): 2543–2563.
    CrossRefPubMed
  52. Barreto R, Waning DL, Gao H, et al. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget. 2016; 7(28): 43442–43460.
    CrossRefPubMed
  53. Chen JL, Colgan TD, Walton KL, et al. The TGF-β Signalling Network in Muscle Development, Adaptation and Disease. Adv Exp Med Biol. 2016; 900: 97–131.
    CrossRefPubMed
  54. Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. 2016; 5(4): 607–616.
    CrossRefPubMed
  55. Palmela C, Velho S, Agostinho L, et al. Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer. J Gastric Cancer. 2017; 17(1): 74–87.
    CrossRefPubMed
  56. Prado CMM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007; 13(11): 3264–3268.
    CrossRefPubMed
  57. Barret M, Antoun S, Dalban C, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014; 66(4): 583–589.
    CrossRefPubMed
  58. Kurk S, Peeters P, Stellato R, et al. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019; 10(4): 803–813.
    CrossRefPubMed
  59. Prado CMM, Lima ISF, Baracos VE, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol. 2011; 67(1): 93–101.
    CrossRefPubMed
  60. Mazzuca F, Onesti CE, Roberto M, et al. Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget. 2018; 9(39): 25714–25722.
    CrossRefPubMed
  61. Kodera Y. More than 6 months of postoperative adjuvant chemotherapy results in loss of skeletal muscle: a challenge to the current standard of care. Gastric Cancer. 2015; 18(2): 203–204.
    CrossRefPubMed
  62. Pin F, Barreto R, Couch ME, et al. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J Cachexia Sarcopenia Muscle. 2019; 10(1): 140–154.
    CrossRefPubMed
  63. Moreira-Pais A, Ferreira R, Gil da Costa R. Platinum-induced muscle wasting in cancer chemotherapy: Mechanisms and potential targets for therapeutic intervention. Life Sci. 2018; 208: 1–9.
    CrossRefPubMed
  64. Nissinen TA, Degerman J, Räsänen M, et al. Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes. Sci Rep. 2016; 6: 32695.
    CrossRefPubMed
  65. Van Gammeren D, Damrauer JS, Jackman RW, et al. The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy. FASEB J. 2009; 23(2): 362–370.
    CrossRefPubMed
  66. Hiensch AE, Bolam KA, Mijwel S, et al. Doxorubicin-induced skeletal muscle atrophy: Elucidating the underlying molecular pathways. Acta Physiol (Oxf). 2020; 229(2): e13400.
    CrossRefPubMed
  67. Denekamp J, Rojas A. Cell kinetics and radiation pathology. Experientia. 1989; 45(1): 33–41.
    CrossRefPubMed
  68. Lefaix JL, Delanian S, Leplat JJ, et al. [Radiation-induced cutaneo-muscular fibrosis (III): major therapeutic efficacy of liposomal Cu/Zn superoxide dismutase]. Bull Cancer. 1993; 80(9): 799–807.
    PubMed
  69. Al-Taie A, Al-Shohani AD, Albasry Z, et al. Current topical trends and novel therapeutic approaches and delivery systems for oral mucositis management. J Pharm Bioallied Sci. 2020; 12(2): 94–101.
    CrossRefPubMed
  70. Sroussi HY, Epstein JB, Bensadoun RJ, et al. Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med. 2017; 6(12): 2918–2931.
    CrossRefPubMed
  71. Arribas L, Hurtós L, Taberna M, et al. Nutritional changes in patients with locally advanced head and neck cancer during treatment. Oral Oncol. 2017; 71: 67–74.
    CrossRefPubMed
  72. Alshadwi A, Nadershah M, Carlson ER, et al. Nutritional considerations for head and neck cancer patients: a review of the literature. J Oral Maxillofac Surg. 2013; 71(11): 1853–1860.
    CrossRefPubMed
  73. Ganju RG, Morse R, Hoover A, et al. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019; 137: 117–124.
    CrossRefPubMed
  74. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22): 2091–2098.
    CrossRefPubMed
  75. Li G, Jiang XY, Qiu Bo, et al. Vicious circle of acute radiation toxicities and weight loss predicts poor prognosis for nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. J Cancer. 2017; 8(5): 832–838.
    CrossRefPubMed
  76. Panje CM, Höng L, Hayoz S, et al. Swiss Group for Clinical Cancer Research (SAKK). Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiat Oncol. 2019; 14(1): 166.
    CrossRefPubMed
  77. Lønbro S, Petersen GB, Andersen JR, et al. Prediction of critical weight loss during radiation treatment in head and neck cancer patients is dependent on BMI. Support Care Cancer. 2016; 24(5): 2101–2109.
    CrossRefPubMed
  78. Ghadjar P, Hayoz S, Zimmermann F, et al. Swiss Group for Clinical Cancer Research (SAKK). Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol. 2015; 10: 21.
    CrossRefPubMed
  79. Chargi N, Bril SI, de Jong PA, et al. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Otorhinolaryngol. 2019; 276(5): 1475–1486.
    CrossRefPubMed
  80. Cho Y, Kim JW, Keum KiC, et al. Prognostic Significance of Sarcopenia With Inflammation in Patients With Head and Neck Cancer Who Underwent Definitive Chemoradiotherapy. Front Oncol. 2018; 8: 457.
    CrossRefPubMed
  81. Mallet R, Modzelewski R, Lequesne J, et al. Prognostic value of sarcopenia in patients treated by Radiochemotherapy for locally advanced oesophageal cancer. Radiat Oncol. 2020; 15(1): 116.
    CrossRefPubMed
  82. van Rijn-Dekker MI, van den Bosch L, van den Hoek JGM, et al. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. Radiother Oncol. 2020; 147: 103–110.
    CrossRefPubMed
  83. Thureau S, Lebret L, Lequesne J, et al. Prospective Evaluation of Sarcopenia in Head and Neck Cancer Patients Treated with Radiotherapy or Radiochemotherapy. Cancers (Basel). 2021; 13(4).
    CrossRefPubMed
  84. Sanders KJC, Hendriks LE, Troost EGC, et al. Early Weight Loss during Chemoradiotherapy Has a Detrimental Impact on Outcome in NSCLC. J Thorac Oncol. 2016; 11(6): 873–879.
    CrossRefPubMed
  85. Shen LJ, Chen C, Li BF, et al. High weight loss during radiation treatment changes the prognosis in under-/normal weight nasopharyngeal carcinoma patients for the worse: a retrospective analysis of 2433 cases. PLoS One. 2013; 8(7): e68660.
    CrossRefPubMed
  86. Olson B, Edwards J, Stone L, et al. Association of Sarcopenia With Oncologic Outcomes of Primary Surgery or Definitive Radiotherapy Among Patients With Localized Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngol Head Neck Surg. 2020; 146(8): 714–722.
    CrossRefPubMed
  87. Ma DW, Cho Y, Jeon MJ, et al. Relationship Between Sarcopenia and Prognosis in Patient With Concurrent Chemo-Radiation Therapy for Esophageal Cancer. Front Oncol. 2019; 9: 366.
    CrossRefPubMed
  88. Yoon HG, Oh D, Ahn YC, et al. Prognostic Impact of Sarcopenia and Skeletal Muscle Loss During Neoadjuvant Chemoradiotherapy in Esophageal Cancer. Cancers (Basel). 2020; 12(4).
    CrossRefPubMed
  89. Liang H, Peng H, Chen L. Prognostic Value of Sarcopenia and Systemic Inflammation Markers in Patients Undergoing Definitive Radiotherapy for Esophageal Cancer. Cancer Manag Res. 2021; 13: 181–192.
    CrossRefPubMed
  90. Lee J, Cho Y, Park S, et al. Skeletal Muscle Depletion Predicts the Prognosis of Patients With Hepatocellular Carcinoma Treated With Radiotherapy. Front Oncol. 2019; 9: 1075.
    CrossRefPubMed
  91. Lin J, Peng J, Qdaisat A, et al. Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer. J Cancer Res Clin Oncol. 2016; 142(12): 2551–2560.
    CrossRefPubMed
  92. Park SEe, Hwang InG, Choi CH, et al. Sarcopenia is poor prognostic factor in older patients with locally advanced rectal cancer who received preoperative or postoperative chemoradiotherapy. Medicine (Baltimore). 2018; 97(48): e13363.
    CrossRefPubMed
  93. Kiyotoki T, Nakamura K, Haraga J, et al. Sarcopenia Is an Important Prognostic Factor in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy. Int J Gynecol Cancer. 2018; 28(1): 168–175.
    CrossRefPubMed
  94. Pielkenrood BJ, van Urk PR, van der Velden JM, et al. Impact of body fat distribution and sarcopenia on the overall survival in patients with spinal metastases receiving radiotherapy treatment: a prospective cohort study. Acta Oncol. 2020; 59(3): 291–297.
    CrossRefPubMed
  95. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008; 26(22): 3770–3776.
    CrossRefPubMed
  96. Tsekoura M, Kastrinis A, Katsoulaki M, et al. Sarcopenia and Its Impact on Quality of Life. Adv Exp Med Biol. 2017; 987: 213–218.
    CrossRefPubMed
  97. Elias R, Hartshorn K, Rahma O, et al. Aging, immune senescence, and immunotherapy: A comprehensive review. Semin Oncol. 2018; 45(4): 187–200.
    CrossRefPubMed
  98. Pawelec G, Derhovanessian E, Larbi A. Immunosenescence and cancer. Crit Rev Oncol/Hematol. 2010; 75(2): 165–172.
    CrossRef
  99. Pedersen BK. Muscles and their myokines. J Exp Biol. 2011; 214(Pt 2): 337–346.
    CrossRefPubMed
  100. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J. 2010; 16(4): 348–353.
    CrossRefPubMed
  101. Verschoor CP, Johnstone J, Millar J, et al. Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol. 2013; 93(4): 633–637.
    CrossRefPubMed
  102. Londhe P, Guttridge DC. Inflammation induced loss of skeletal muscle. Bone. 2015; 80: 131–142.
    CrossRefPubMed
  103. Tsukamoto H, Fujieda K, Miyashita A, et al. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Cancer Res. 2018; 78(17): 5011–5022.
    CrossRefPubMed
  104. Kim EY, Lee HY, Kim YS, et al. Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer. J Thorac Oncol. 2015; 10(12): 1795–1799.
    CrossRefPubMed
  105. Ábrigo J, Campos F, Simon F, et al. TGF-β requires the activation of canonical and non-canonical signalling pathways to induce skeletal muscle atrophy. Biol Chem. 2018; 399(3): 253–264.
    CrossRefPubMed
  106. Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693): 544–548.
    CrossRefPubMed
  107. Suzuki Y, Okamoto T, Fujishita T, et al. Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer. Lung Cancer. 2016; 101: 92–97.
    CrossRefPubMed
  108. Wherry EJ. T cell exhaustion. Nat Immunol. 2011; 12(6): 492–499.
    CrossRefPubMed
  109. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012; 7(5): e37563.
    CrossRefPubMed
  110. Nishioka N, Uchino J, Hirai S, et al. Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. J Clin Med. 2019; 8(4).
    CrossRefPubMed
  111. Heidelberger V, Goldwasser F, Kramkimel N, et al. Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs. 2017; 35(4): 436–441.
    CrossRefPubMed
  112. Daly LE, Power DG, O'Reilly Á, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017; 116(3): 310–317.
    CrossRefPubMed
  113. Revel MP, Raynard B, Pigneur F, et al. Sarcopenia and toxicity of the anti-PD1 inhibitors in real-life lung cancer patients: Results from the French Nationwide SCAN study. J Clin Oncol. 2018; 36(15_suppl): e21066–e21066.
    CrossRef
  114. Heidelberger V, Kramkimel N, Huillard O, et al. Sarcopenia associated with a body mass index (BMI) > 25 kg/m2 predicts severe acute toxicity of nivolumab and pembrolizumab in melanoma patients. Ann Oncol. 2016; 27: vi387.
    CrossRef
  115. Massicotte MH, Borget I, Broutin S, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab. 2013; 98(6): 2401–2408.
    CrossRefPubMed
  116. Veasey-Rodrigues H, Parsons HA, Janku F, et al. A pilot study of temsirolimus and body composition. J Cachexia Sarcopenia Muscle. 2013; 4(4): 259–265.
    CrossRefPubMed
  117. Bozzetti F. Chemotherapy-Induced Sarcopenia. Curr Treat Options Oncol. 2020; 21(1): 7.
    CrossRefPubMed
  118. Cortellini A, Verna L, Porzio G, et al. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report. Thorac Cancer. 2019; 10(2): 347–351.
    CrossRefPubMed
  119. Shiroyama T, Nagatomo I, Koyama S, et al. Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci Rep. 2019; 9(1): 2447.
    CrossRefPubMed
  120. Kano M, Hihara J, Tokumoto N, et al. Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients. Int J Clin Oncol. 2021; 26(3): 523–531.
    CrossRefPubMed
  121. Reisinger KW, Bosmans JW, Uittenbogaart M, et al. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery. Ann Surg Oncol. 2015; 22(13): 4445–4452.
    CrossRefPubMed
  122. Elliott JA, Doyle SL, Murphy CF, et al. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer. Ann Surg. 2017; 266(5): 822–830.
    CrossRefPubMed
  123. Paireder M, Asari R, Kristo I, et al. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer. Eur J Surg Oncol. 2017; 43(2): 478–484.
    CrossRefPubMed
  124. Dijksterhuis WPM, Pruijt MJ, van der Woude SO, et al. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J Cachexia Sarcopenia Muscle. 2019; 10(1): 199–206.
    CrossRefPubMed
  125. Ota T, Ishikawa T, Endo Y, et al. Skeletal muscle mass as a predictor of the response to neo-adjuvant chemotherapy in locally advanced esophageal cancer. Med Oncol. 2019; 36(2): 15.
    CrossRefPubMed
  126. Voisinet M, Venkatasamy A, Alratrout H, et al. How to Prevent Sarcopenia Occurrence during Neoadjuvant Chemotherapy for Oesogastric Adenocarcinoma? Nutr Cancer. 2021; 73(5): 802–808.
    CrossRefPubMed
  127. Dalal S, Hui D, Bidaut L, et al. Relationships among body mass index, longitudinal body composition alterations, and survival in patients with locally advanced pancreatic cancer receiving chemoradiation: a pilot study. J Pain Symptom Manage. 2012; 44(2): 181–191.
    CrossRefPubMed
  128. Fogelman DR, Holmes H, Mohammed K, et al. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014; 5(4): 307–313.
    CrossRefPubMed
  129. Antoun S, Bayar MA, Dyevre V, et al. No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer. BMC Cancer. 2019; 19(1): 847.
    CrossRefPubMed
  130. Kobayashi T, Kawai H, Nakano O, et al. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies. BMC Cancer. 2018; 18(1): 756.
    CrossRefPubMed
  131. Atlan P, Bayar MA, Lanoy E, et al. Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study. Support Care Cancer. 2017; 25(11): 3365–3373.
    CrossRefPubMed
  132. Kakinuma K, Tsuruoka H, Morikawa K, et al. Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer. Thorac Cancer. 2018; 9(1): 99–104.
    CrossRefPubMed
  133. Xiao DY, Luo S, O'Brian K, et al. Longitudinal Body Composition Changes in Diffuse Large B-cell Lymphoma Survivors: A Retrospective Cohort Study of United States Veterans. J Natl Cancer Inst. 2016; 108(11).
    CrossRefPubMed
  134. Grossberg AJ, Chamchod S, Fuller CD, et al. Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2016; 2(6): 782–789.
    CrossRefPubMed
  135. Chauhan NS, Samuel SR, Meenar N, et al. Sarcopenia in male patients with head and neck cancer receiving chemoradiotherapy: a longitudinal pilot study. PeerJ. 2020; 8: e8617.
    CrossRefPubMed
  136. Op den Kamp CMH, De Ruysscher DKM, van den Heuvel M, et al. Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer. J Cachexia Sarcopenia Muscle. 2014; 5(2): 127–137.
    CrossRefPubMed
  137. Kiss N, Beraldo J, Everitt S. Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival. Support Care Cancer. 2019; 27(7): 2657–2664.
    CrossRefPubMed
  138. Murimwa GZ, Venkat PS, Jin W, et al. Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery. J Gastrointest Oncol. 2017; 8(5): 808–815.
    CrossRefPubMed
  139. Shiba S, Shibuya K, Katoh H, et al. No Deterioration in Clinical Outcomes of Carbon Ion Radiotherapy for Sarcopenia Patients with Hepatocellular Carcinoma. Anticancer Res. 2018; 38(6): 3579–3586.
    CrossRefPubMed
  140. Matsubara Y, Nakamura K, Matsuoka H, et al. Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy. Anticancer Res. 2019; 39(2): 933–939.
    CrossRefPubMed
  141. Couderc AL, Muracciole X, Nouguerede E, et al. HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer. J Nutr Health Aging. 2020; 24(2): 205–209.
    CrossRefPubMed
  142. Ferini G, Cacciola A, Parisi S, et al. Curative Radiotherapy in Elderly Patients With Muscle Invasive Bladder Cancer: The Prognostic Role of Sarcopenia. In Vivo. 2021; 35(1): 571–578.
    CrossRefPubMed
  143. Zhang G, Li X, Sui C, et al. Incidence and risk factor analysis for sarcopenia in patients with cancer. Oncol Lett. 2016; 11(2): 1230–1234.
    CrossRefPubMed
  144. Magri V, Gottfried T, Di Segni M, et al. Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients. Cancer Manag Res. 2019; 11: 8201–8207.
    CrossRefPubMed
  145. Popinat G, Cousse S, Goldfarb L, et al. Sub-cutaneous Fat Mass measured on multislice computed tomography of pretreatment PET/CT is a prognostic factor of stage IV non-small cell lung cancer treated by nivolumab. Oncoimmunology. 2019; 8(5): e1580128.
    CrossRefPubMed
  146. Cortellini A, Bozzetti F, Palumbo P, et al. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study. Sci Rep. 2020; 10(1): 1456.
    CrossRefPubMed
  147. Roch B, Coffy A, Jean-Baptiste S, et al. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer. 2020; 143: 19–26.
    CrossRefPubMed
  148. Petrova MP, Donev IS, Radanova MA, et al. Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. Clin Exp Immunol. 2020; 202(3): 353–362.
    CrossRefPubMed
  149. Ichihara E, Harada D, Inoue K, et al. The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer. Lung Cancer. 2020; 139: 140–145.
    CrossRefPubMed
  150. Minami S, Ihara S, Tanaka T, et al. Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer. World J Oncol. 2020; 11(1): 9–22.
    CrossRefPubMed
  151. Katayama Y, Shimamoto T, Yamada T, et al. Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. J Clin Med. 2019; 9(1).
    CrossRefPubMed
  152. Tsukagoshi M, Yokobori T, Yajima T, et al. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (Baltimore). 2020; 99(7): e19059.
    CrossRefPubMed
  153. Takada K, Yoneshima Y, Tanaka K, et al. Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. J Cancer Res Clin Oncol. 2020; 146(5): 1217–1225.
    CrossRefPubMed
  154. Kichenadasse G, Miners JO, Mangoni AA, et al. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2020; 6(4): 512–518.
    CrossRefPubMed
  155. Kim YY, Lee J, Jeong WK, et al. Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors. Gastric Cancer. 2021; 24(2): 457–466.
    CrossRefPubMed
  156. Qayyum A, Bhosale P, Aslam R, et al. Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdom Radiol (NY). 2021; 46(3): 1008–1015.
    CrossRefPubMed
  157. Akce M, Liu Y, Zakka K, et al. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. Am J Clin Oncol. 2021; 44(2): 74–81.
    CrossRefPubMed
  158. Hu JB, Ravichandran S, Rushing C, et al. Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. Anticancer Res. 2020; 40(9): 5245–5254.
    CrossRefPubMed
  159. Shimizu T, Miyake M, Hori S, et al. Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. Diagnostics (Basel). 2020; 10(5).
    CrossRefPubMed
  160. Fukushima H, Fukuda S, Moriyama S, et al. Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report. Anticancer Drugs. 2020; 31(8): 866–871.
    CrossRefPubMed
  161. Gyawali B, Shimokata T, Honda K, et al. Muscle wasting associated with the long-term use of mTOR inhibitors. Mol Clin Oncol. 2016; 5(5): 641–646.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Oncology in Clinical Practice

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice